Neuroscience Trials Australia

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 2001-01-01

Employees: 51

Market Cap: -

Website: https://neurosciencetrialsaustralia.com

Clinical Trials

DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval

Phase 3

Completed

Conditions: Ischemic Stroke

Interventions: Other: Direct endovascular clot retrieval
Other: Bridging thrombolysis followed by ECR

First Posted Date: 2018-04-11

Last Posted Date: 2022-06-16

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 295

Registration Number: NCT03494920

Locations: 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇨🇳
Shanxi People's Hospital, Shanxi, Taiyuan, China
🇨🇳
China-Japan Union Hospital of Jilin University, Jilin, China

and more 30 locations

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Phase 2

Completed

Conditions: Intracerebral Haemorrhage

Interventions: Drug: Normal saline
Drug: Tranexamic Acid

First Posted Date: 2017-12-29

Last Posted Date: 2023-09-28

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 201

Registration Number: NCT03385928

Locations: 🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 22 locations

Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase

First Posted Date: 2017-11-13

Last Posted Date: 2020-03-04

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 300

Registration Number: NCT03340493

Locations: 🇦🇺
Ballarat Health Services, Ballarat, Victoria, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Albury Hospital, Albury, New South Wales, Australia

and more 25 locations

Trial of EXenatide in Acute Ischaemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Exenatide Injection

First Posted Date: 2017-09-19

Last Posted Date: 2021-09-14

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 350

Registration Number: NCT03287076

Locations: 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia
🇫🇮
Helsinki University Hospital, Helsinki, Finland

and more 12 locations

Deferiprone to Delay Dementia (The 3D Study)

Phase 2

Completed

Conditions: Mild Cognitive Impairment
Prodromal Alzheimer's Disease
Mild Alzheimer's Disease

Interventions: Drug: Deferiprone 600mg delayed release tablets
Drug: Placebo Oral Tablet

First Posted Date: 2017-07-31

Last Posted Date: 2024-07-03

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 81

Registration Number: NCT03234686

Locations: 🇦🇺
Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia
🇦🇺
KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia

and more 5 locations

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Triumeq

First Posted Date: 2016-08-16

Last Posted Date: 2019-08-22

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 43

Registration Number: NCT02868580

Locations: 🇦🇺
Westmead Hospital, Parramatta, New South Wales, Australia
🇦🇺
Macquarie Neurology, North Ryde, New South Wales, Australia
🇦🇺
Calvary Health Care Bethlehem, Caulfield South, Victoria, Australia

and more 1 locations

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Tissue Plasminogen Activator

First Posted Date: 2015-03-13

Last Posted Date: 2018-03-30

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 202

Registration Number: NCT02388061

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia

and more 15 locations

A Very Early Rehabilitation Trial

Not Applicable

Completed

Conditions: Stroke

Interventions: Other: Standard care
Other: Standard Care + VEM

First Posted Date: 2013-05-03

Last Posted Date: 2015-04-15

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 2014

Registration Number: NCT01846247

Locations: 🇦🇺
Florey Institute for Neuroscience and Mental health, Melbourne, Victoria, Australia

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Phase 2

Completed

Conditions: Stroke
Intracerebral Haemorrhage

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2012-10-08

Last Posted Date: 2020-02-26

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 100

Registration Number: NCT01702636

Locations: 🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia
🇦🇺
Frankston Hospital, Frankston, Victoria, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

and more 8 locations

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Phase 3

Completed

Conditions: Stroke

Interventions: Drug: Tissue Plasminogen Activator (Alteplase)
Drug: Placebo

First Posted Date: 2012-04-19

Last Posted Date: 2018-08-31

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 45

Registration Number: NCT01580839

Locations: 🇨🇳
China Medical University Hospital, Taichung, Taiwan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy